Clinical Trial Detail

NCT ID NCT03038477
Title A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Colorado, Denver
Indications

pancreatic ductal adenocarcinoma

Therapies

Durvalumab

Age Groups: adult senior

No variant requirements are available.